معلومات عن هذه الحلقة
When does a neuroendocrine tumor warrant a second look? Join Dr. Nisha Mohindra and Dr. Rahul Aggarwal as they explore the clinical, imaging, and pathologic clues that distinguish neuroendocrine tumors from neuroendocrine carcinomas. Learn how multidisciplinary assessment, pathology review, and repeat biopsy can help resolve diagnostic uncertainty in challenging cases.
Visit https://www.atpointofcare.com/library/2759.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
This podcast is powered by Pinecast.
الإنجليزية
الولايات المتحدة
النص 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
البحث في الحلقات الماضية
البحث في الحلقات السابقة من Hematology / Oncology @Point of Care Podcasts.
حلقات أخرى في هذا البودكاست
This expert-led podcast explores the rapidly evolving perioperative treatment landscape in muscle-invasive bladder cancer. Faculty will discuss pivotal data from NIAGARA, KEYNOTE-905, and KEYNOTE-B15, and consider how recent advances are expanding systemic treatment options, including for patients …
This expert-led podcast explores practical treatment selection in the evolving perioperative landscape for muscle-invasive bladder cancer. Faculty will discuss how to assess treatment eligibility, navigate immunotherapy-based and antibody-drug conjugate–based options, and coordinate care across spe…
Stay ahead of evolving endocrine resistance in HR-positive, HER2-negative advanced breast cancer. Discover how ESR1 mutations are reshaping treatment decisions, and explore expert perspectives on mutation testing, oral SERDs, and emerging serial monitoring strategies that may help identify resistan…
This final episode of a three-part expert-led podcast series explores the emerging toxicity landscape as immunotherapy- and antibody-drug conjugate–based regimens enter the treatment of muscle-invasive bladder cancer. Faculty will discuss the mechanistic basis for these side effects, practical moni…
Explore the evolving role of oral SERDs in HR-positive, HER2-negative advanced breast cancer. Hear expert perspectives on ESR1 mutation testing, treatment selection and sequencing, emerging combination strategies, circulating tumor DNA (ctDNA) monitoring, and safety considerations that may inform i…
إخلاء المسؤولية: البودكاست والأعمال الفنية المضمنة في هذه الصفحة مأخوذة من @Point of Care، وهي مملوكة لمالكها وليست تابعة لشركة Listen Notes, Inc أو معتمدة منها.
تعديل
شكراً على مساعدتنا في الحفاظ على قاعدة بيانات البودكاست مُحدَّثة.
